Saito R, Ishiharada N, Ban Y, Honda K, Takano Y, Kamiya H
Department of Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, Japan.
Brain Res. 1994 May 16;646(1):170-4. doi: 10.1016/0006-8993(94)90073-6.
Two subtypes of arginine vasopressin (AVP) receptors (V1 and V2) have been distinguished. In this study, we examined the characteristics of AVP binding in rat hippocampus and the effects of bilateral adrenalectomy and adrenal steroids on its [3H]AVP binding. [3H]AVP binding to rat liver and the hippocampal membranes was strongly inhibited by the V1 antagonist, OPC-21268. ADX resulted in a significant decrease in the Bmax of AVP binding in the hippocampus. Chronic treatment with aldosterone and corticosterone restored the ADX-induced reduction, but treatment with dexamethasone did not. These results suggest that the AVP V1 receptor in the hippocampus is regulated by adrenocortical neuroregulatory functions.
精氨酸加压素（AVP）受体已被区分为两种亚型（V1和V2）。在本研究中，我们检测了大鼠海马中AVP结合的特征，以及双侧肾上腺切除术和肾上腺类固醇对其[3H]AVP结合的影响。V1拮抗剂OPC - 21268强烈抑制[3H]AVP与大鼠肝脏和海马膜的结合。肾上腺切除术导致海马中AVP结合的Bmax显著降低。醛固酮和皮质酮的长期治疗可恢复肾上腺切除所致的降低，但地塞米松治疗则不能。这些结果表明，海马中的AVP V1受体受肾上腺皮质神经调节功能的调控。
